Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on Tenet Healthcare (NYSE:THC) and raises the price target from $156 to $171.
July 29, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Andrew Mok maintains an Overweight rating on Tenet Healthcare and raises the price target from $156 to $171, indicating a positive outlook for the stock.
The raised price target from $156 to $171 by Barclays suggests increased confidence in Tenet Healthcare's future performance. The Overweight rating indicates that the stock is expected to outperform the market, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100